+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience



Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience



Cancer 112(4): 892-899



Carboplatin-based regimens have demonstrated activity in pediatric patients with low-grade glioma (LGG). However, carboplatin hypersensitivity reaction (Cb HSR) represents a common and limiting factor for the continuation of therapy. The objectives of this study were to describe the prevalence, characteristics, and management of Cb HSR and to detail their impact on outcome. The authors conducted a comprehensive, national, retrospective review of children who were diagnosed with LGG between 1985 and 2004 and received treatment with carboplatin. One hundred five patients from 10 Canadian centers were included. The median patient age at diagnosis was 3.5 years (range, 0.3-16.8 years), and 33 patients (31.4%) had neurofibromatosis type 1. Carboplatin was administered monthly in 46 children and weekly in 59 children. Forty-four patients (41.9%) developed Cb HSR after a median of 10.5 infusions (range, 3-39 infusions). Cb HSR occurred significantly earlier among children on the weekly schedule (4.4 months vs 9.1 months; P = .02). The first allergic reaction was grade I or II in 36 patients (82%). The cumulative incidence of Cb HSR increased with the number of infusions, and there was no evidence of a plateau. The only predictive factor was being a girl rather than a boy (P = .02). Thirty-four of 44 patients with Cb HSR were re-exposed to carboplatin, and 24 of 34 patients (70.5%) had recurrent Cb HSR. A desensitization approach did not provide any advantage compared with premedication alone for altering Cb HSR. The median number of additional Cb infusions delivered was 4 (range, 0.5-34 infusions). The effect of Cb HSR on the 5-year progression-free survival rate was not statistically significant (P = .1). Forty-two percent of children with LGG who received carboplatin regimens experienced Cb HSR. Most rechallenged children had recurrent Cb HSR despite Cb HSR-altering regimens. Cb HSR did not have an impact on progression-free survival.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 020688110

Download citation: RISBibTeXText

PMID: 18098210

DOI: 10.1002/cncr.23249


Related references

Carboplatin hypersensitivity reaction in pediatric low grade glioma (LGG) patients: A national experience. On behalf of the Canadian Pediatric Brain Tumor Consortium. Journal of Clinical Oncology 24(18_suppl): 9053-9053, 2016

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology 19(8): 1135-1144, 2017

Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. Journal of Clinical Oncology 34(29): 3537-3543, 2016

Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma. Pediatric Blood and Cancer 63(1): 21-26, 2016

Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Low-Grade Glioma: How Far Should we Push?. Pediatric Blood and Cancer 63(1): 9-10, 2016

Ltbk-01. Updates On The Phase Ii And Re-Treatment Study Of Azd6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (Pbtc) Study. Neuro-Oncology 20(suppl_2): i214, 2018

Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103(12): 2636-2642, 2005

Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium. RadioTherapy and Oncology 81(1): 33-38, 2006

Hgg-39. Effect Of Tumor Treating Fields In Children With Recurrent Or Progressive High-Grade Glioma And Ependymoma (Pediatric Brain Tumor Consortium Pbtc048). Neuro-Oncology 20(suppl_2): i97, 2018

Lgg-02. A Phase Ii Prospective Trial Of Selumetinib In Children With Recurrent/Progressive Pediatric Low-Grade Glioma (Plgg) With A Focus Upon Optic Pathway/Hypothalamic Tumors And Visual Acuity Outcomes: A Pediatric Brain Tumor Consortium (Pbtc) Study, Pbtc-029B. Neuro-Oncology 21(Supplement_2): ii98-ii99, 2019

Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. Journal of Nuclear Medicine 52(2): 188-195, 2011

Dipg-22. A Phase 1 Trial Of The Histone Deacetylase Inhibitor Panobinostat In Pediatric Patients With Recurrent Or Refractory Diffuse Intrinsic Pontine Glioma: A Pediatric Brain Tumor Consortium (Pbtc) Study. Neuro-Oncology 20(suppl_2): i53, 2018

Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Supportive Care in Cancer 20(2): 385-393, 2012

Choroid plexus tumors in children less than 36 months: the Canadian Pediatric Brain Tumor Consortium (CPBTC) experience. Child's Nervous System 27(2): 259-264, 2011

Carboplatin Hypersensitivity Reactions in Pediatric Low Grade Glioma Are Protocol Specific and Desensitization Shows Poor Efficacy. Pediatric Blood and Cancer 63(1): 17-20, 2016